April 26th, 2012 tmccoy
by: Jonathan Macri, Esq. Bayer AG, one of the world’s largest and most successful manufacturers of pharmaceuticals, has finally begun to get an idea of just how much their failure to warn users of the dangers of one of their most popular drugs is going to cost them. The company recently announced that settlements in [...]
Posted in Defective Drugs, Latest News by: tmccoy
No Comments
April 26th, 2012 tmccoy
by: Matthew McCauley, Esq. Emergency personnel who first responded to the American tragedy of the World Trade Center were put at a high risk due to exposure to toxic dust and chemicals. These victims, which include loved ones who lost someone, are being compensated by the victims’ compensation fund. Health conditions being compensated for include [...]
Posted in Environmental, Latest News, Personal Injury by: tmccoy
No Comments
April 25th, 2012 tmccoy
by: Stephanie Herschaft, Esq. Over 1000 Australians have joined a multimillion-dollar class action against Johnson and Johnson after receiving controversial metal-on-metal hip implants manufactured by DePuy Orthopaedics, a subsidiary of Johnson and Johnson. An article in The Courier Mail chronicles the story of Stuart Cain, a plaintiff in the class action. In June 2007, Cain [...]
Posted in Defective Medical Devices, Latest News by: tmccoy
No Comments
April 25th, 2012 tmccoy
by: Jonathan Macri, Esq. Boston Scientific has just issued a warning in relation to two of its implantable defibrillators, bringing the company under fire for the second time this year. The defibrillators at issue, Cognis and Telogen, are associated with 26 confirmed reports of malfunctions, and the warning comes after one of these incidents resulted [...]
Posted in Defective Medical Devices, Latest News by: tmccoy
No Comments
April 25th, 2012 tmccoy
by: Gary Falkowitz, Esq. Avodart is used to help reduce the chance of developing acute urinary retention (sudden inability to urinate) and also to treat the enlargement of the prostate gland. Avodart is a dutasteride medication manufactured by GlaxoSmithKline and approved by the Food and Drug Administration (FDA) in October 2002. Avodart is in a [...]
Posted in Defective Drugs, Latest News by: tmccoy
No Comments
April 25th, 2012 tmccoy
by: Matthew McCauley, Esq. Osteopenia is a medical condition in which the density in a woman’s bone increases the risks of breaks. Treatment of this condition includes bisphosphonate prescription drugs such as Fosamax, Actonel, and Boniva. Recent studies have shown that long-term exposure to these drugs is causing atypical fractures in women. What this means [...]
Posted in Defective Drugs, Latest News by: tmccoy
No Comments
April 24th, 2012 tmccoy
by: Matthew McCauley, Esq. Attorney Matthew McCauley shares a case study about a client named “Jane” who suffered a very painful femur fracture due to overexposure of a prescription drug. Jane was prescribed the prescription drug Fosamax for osteopenia, which is usually a precursor for osteoporosis. These medical conditions are a loss of bone density, [...]
Posted in Defective Drugs, Latest News by: tmccoy
No Comments
April 24th, 2012 tmccoy
by: Jay Breakstone, Esq. One would think that with the recent BP Oil Spill settlement, all is right with the world and we can happily move on to the next environmental disaster. But after all is said and done, the question remains: What happened and who is to blame? Answering questions of liability become much [...]
Posted in Environmental, Latest News by: tmccoy
No Comments
April 24th, 2012 tmccoy
by: Stephanie Herschaft, Esq. Actos (pioglitazone hydrochloride), an oral anti-diabetic drug, is authorized in Canada (and in the United States) to help decrease the blood glucose levels not controlled by diet and exercise alone, in patients who suffer from type 2 diabetes mellitus. ACTOS (pioglitazone hydrochloride) can also be taken with sulfonylurea or metformin when [...]
Posted in Defective Drugs, Latest News by: tmccoy
No Comments
April 24th, 2012 tmccoy
by: Jonathan Macri, Esq. At last, the Food and Drug Administration is giving the same priority to drugs that have been released on the market to ones that are still in the pre-market review phase, and amidst an environment where new drug defects are seemingly found every day, the FDA’s new priorities seem to be [...]
Posted in Defective Drugs, Latest News by: tmccoy
No Comments